The Trump administration on Monday barred US citizens in the Democratic Republic of the Congo from returning home amid an Ebola outbreak that continues to outpace response efforts.

Reuters first reported late Monday that Americans currently in the DRC or those who have recently traveled to the Ebola-stricken country have been put on a "do-not-board" list. They cannot travel back to the US until they have spent 21 days in a third country. The order, taken under a transportation authority known as Title 49, was independently confirmed by Politico on Tuesday.

Both outlets noted that roughly two dozen Americans who had been set to board flights home on Tuesday have already been blocked by the new rule. It remains unclear if the bar also applies to government workers. The Centers for Disease Control and Prevention has at least two dozen employees working in the DRC.

Read full article

Comments

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed.

In an all-day meeting, members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine.

Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good.

Read full article

Comments